ETFs Invest Heavily in Eli Lilly on November 11

ETFs Show Strong Interest in Eli Lilly

On November 11, Eli Lilly (LLY) attracted considerable attention from exchange-traded funds (ETFs), with a net investment of $154.5 million. This activity marks a continuation of positive inflows into the stock over three days, coming after two preceding days of net outflows totaling $82.7 million.

Recent ETF Movement

ETFs have exhibited a noticeable buying trend with 49 funds increasing their holdings while 11 reduced theirs. This investment pattern reflects the continuing interest in Eli Lilly, following net buys of $38.9 million on November 10 and $23.3 million on November 9. The initial declines in the stock occurred on November 5 and November 6, with outflows of $57 million and $25.7 million, respectively.

Major Buyers and Their Contributions

The leading ETFs contributing to the recent purchase of Eli Lilly shares include:

• SPY: +51,744 shares valued at $74.4 million (1.75% weight)
• XLV: +46,452 shares valued at $66.8 million (16.82% weight)
• SPYM: +3,942 shares valued at $5.7 million
• ACWI: +2,750 shares valued at $4.0 million (1.14% weight)
• SPYG: +2,128 shares valued at $3.1 million (3.30% weight)
• IWF: +1,764 shares valued at $2.5 million (3.63% weight)
• JGRO: +1,499 shares valued at $2.2 million (3.65% weight)
• GPIX: +942 shares valued at $1.4 million (1.76% weight)

Among these, the SPY ETF was the most significant contributor, followed closely by XLV. Eli Lilly's prominence in the XLV ETF is particularly notable, with it holding the largest percentage of weight at 16.82%.

Recent Trends in ETF Trading

Analyzing the last five trading days reveals that ETFs have demonstrated net buying behavior on three occasions, contrasting with two days of selling. This trend is a strong indicator of growing interest in Eli Lilly among institutional investors.

Summarized ETF Activity

• November 11: +$154.5 million (49 buyers, 11 sellers)
• November 10: +$38.9 million (40 buyers, 12 sellers)
• November 9: +$23.3 million (37 buyers, 19 sellers)
• November 6: -$25.7 million (51 buyers, 16 sellers)
• November 5: -$57.0 million (47 buyers, 13 sellers)

A Closer Look at Eli Lilly

Eli Lilly is a leading pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of a wide array of human medicines, available in nearly 90 countries worldwide. Its strong product portfolio includes top offerings in the cardiometabolic health arena, notably Mounjaro, which targets type 2 diabetes, and Zepbound, aimed at obesity and sleep apnea management. Other products include Trulicity and Jardiance, along with a range of insulin products.

The financial metrics of Eli Lilly indicate robust growth; its trailing-12-month revenue reached $86.46 billion, reflecting a 46.3% increase year-over-year. The company maintains a gross margin of 83.6% and a net margin of 31.9%. Current trading metrics show a price-to-earnings ratio of 46.89, while the price-to-book and price-to-sales ratios stand at 33.36 and 14.94, respectively. With a market capitalization of approximately $1.34 trillion, Eli Lilly has earned a GF Score of 98, indicating strong performance potential.

Currently, the share price of $1,427.28 remains below the GF Value estimation of $1,610.19, with a modest dividend yield of 0.47%. Eli Lilly has also seen a notable return of 33.45% year to date, underscoring its strong investment appeal.